Skip to content
All compound profiles

EVIDENCE PROFILE / PUBLISHED

GHK-Cu

A copper(II) complex of the tripeptide glycyl-histidyl-lysine, supported mainly by cell and animal tissue-remodelling work and a very small topical human literature.

Aliases reviewed
Copper tripeptide-1, Copper-GHK, Cu-GHK, Glycyl-L-histidyl-L-lysine copper(II)
Sources checked
2026-09-15
Editorial status
published

Evidence at a glance

Human
LimitedOne very small randomized study of a topical skin-care regimen.
Animal/cell
Not rated
Approved medicine
Not rated

Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.

PREPPY BOY ASKS

“Copper tripeptide in a finished cream, a cell-culture reagent, and an injectable bulk substance are three different evidence questions.”

GHK-Cu has a plausible tissue-remodelling story and decades of laboratory work. The clinical record is much thinner, and evidence for a cosmetic cream cannot be transferred to an injectable material.

Identity and established aliases

GHK is the tripeptide glycyl-L-histidyl-L-lysine, first isolated from human plasma. It binds copper(II) to form GHK-Cu. Cosmetic ingredient lists may use copper tripeptide-1, but naming alone does not establish concentration, chemical state, delivery, purity, or equivalence to a research vial.

Why researchers study it

GHK-Cu has been investigated as a modulator of extracellular-matrix production and turnover. Cultured fibroblast work reported increased collagen production, while rat wound-chamber work reported increased extracellular-matrix accumulation. These findings suggest pathways worth studying in tissue repair; they do not establish a clinical outcome.

Approved medicines and investigational uses

No GHK-Cu active-ingredient record was returned by Health Canada's Drug Product Database under the reviewed name. The reviewed FDA material does not identify an FDA-approved injectable GHK-Cu drug. FDA places injectable GHK-Cu among substances with limited human safety data and potential immunogenicity concerns; non-injectable compounding status is a separate, still-evolving regulatory question.

Human research has primarily examined topical multi-ingredient skin-care regimens or wound-related contexts. A cosmetic ingredient's lawful use and a drug approval are not the same regulatory category.

What human studies show

In a randomized study after carbon-dioxide laser resurfacing, 13 participants completed topical regimens with or without GHK-Cu-containing products. Blinded and computer assessments found no significant difference in erythema, wrinkles, or overall skin quality; a questionnaire favoured the GHK-Cu regimen for patient satisfaction. The sample was tiny and the intervention was a skin-care regimen, not isolated injected GHK-Cu.

That result does not establish wound treatment, anti-aging, hair growth, systemic effects, or safety by other routes. FDA describes human safety information for injectable GHK-Cu as limited.

What cells and animal studies show

Cultured human fibroblasts produced more collagen under specific GHK-Cu conditions. In rat wound chambers, investigators reported increased extracellular-matrix accumulation. These controlled models support a tissue-remodelling hypothesis, but model exposure and endpoints differ from a finished human product and from patient-centred outcomes.

Popular claims include reducing wrinkles, reversing skin aging, growing hair, accelerating wounds, and producing broad anti-inflammatory or regenerative effects. The reviewed human evidence is insufficient for those broad statements. Positive cell markers and consumer satisfaction after a combined skin regimen are not proof of clinical regeneration.

What remains uncertain

Larger independent human trials, standardized formulations, route-specific absorption, clinically meaningful endpoints, and long-term safety remain gaps. Injectable use raises additional questions about aggregation, impurities, immunogenicity, sterility, endotoxin, and copper exposure that topical studies do not answer.

What this profile is—and is not

Published after separating topical cosmetic research from injectable-route claims and catalogue identity.

This is sourced education, not medical advice or a personal-use recommendation. It does not validate the identity, purity, sterility, safety, or effectiveness of a catalogue material.